Comparative Pharmacology
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROLOTION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROLOTION.
METRO I.V. IN PLASTIC CONTAINER vs METROLOTION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Metrolotion is a formulation of metronidazole, a nitroimidazole antibiotic. Its exact mechanism is not fully understood, but it is believed to involve reduction of the nitro group in anaerobic bacteria and protozoa, leading to DNA disruption and cell death. It also has anti-inflammatory and immunosuppressive properties, possibly by inhibiting neutrophil chemotaxis and reactive oxygen species.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
Topical metronidazole (Metrolotion) 1%: Apply a thin layer to affected areas once daily.
None Documented
None Documented
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Terminal elimination half-life is 18-24 hours; allows once-daily dosing.
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)